Mar 18, 2026 ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Feb 4, 2026 ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dec 18, 2025 ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Dec 10, 2025 ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Dec 1, 2025 ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Nov 12, 2025 ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights